Dr. Yanmin Zhao 赵妍敏
Chief Physician
Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of blood disorders and hematologic malignancies, including aplastic anemia, acute and chronic leukemia, and MDS. Expertise in hematopoietic stem cell transplantation and management of post-transplant complications.
Dr. Zhao has over 10 years of clinical experience in diagnosing and treating common and complex blood disorders. Focus areas include targeted therapy, immunotherapy, hematopoietic stem cell transplantation, and management of related complications. Dr. Zhao integrates international advances into clinical practice to improve patient outcomes.
Professional roles
- Member, Youth Committee of the Hematologic Oncology Professional Committee, China Anti-Cancer Association (2nd Term)
- Vice Chair, Youth Committee of the Hematology Branch, Zhejiang Medical Association
- Member, Youth Committee of the Hematology Branch, Zhejiang Immunological Society
- Secretary, Hematology Professional Group for Clinical Trials, The First Affiliated Hospital, Zhejiang University School of Medicine
Name order: in Chinese the family name comes first (Zhao Yanmin). Papers usually list the name as Yanmin Zhao or Zhao Y.
Selected publications
105 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- Lancet Haematol, 2026 (senior author): Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial. PubMed 42532067
- Lancet Reg Health West Pac, 2026 (first author): Low-dose chidamide maintenance therapy following allogeneic hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia or lymphomas: a phase II, open-label, multicenter, single-arm trial. PubMed 42518787
- Blood Cancer J, 2026 (first author): Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53-mutated AML/MDS undergoing allogeneic HCT. PubMed 42362536
- Innovation (Camb), 2026 (senior author): Donor leukocyte telomere length emerges as a prognostic factor for transplantation outcomes. PubMed 41789132
- Bone Marrow Transplant, 2025 (senior author): Machine learning-based prediction of G-CSF-induced hematopoietic stem cell mobilization outcomes in healthy volunteers. PubMed 40615536
- Leukemia, 2025 (first author): Impact of TP53 variants and germline mutations on allogeneic stem cell transplantation outcomes in acute myeloid leukemia and myelodysplastic neoplasms. PubMed 40659988
- Chin J Cancer Res, 2025 (first author): Impact of clinical characteristics and genetic profiles on outcomes of allogeneic stem cell transplantation with sorafenib maintenance in FLT3-ITD acute myeloid leukemia patients: A multi-center, retrospective study. PubMed 40979666
- Stem Cell Res Ther, 2025 (first author): Salvage treatment of steroid-refractory acute GVHD with the off-the-shelf product of human umbilical cord mesenchymal stromal cells: a multicenter, open label, phase Ib/IIa trial. PubMed 40597363
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion